Table 2.
Antiviral efficacy of F18 in combination with eight FDA-approved antiretroviral compounds against HIV-1NL4-3 in PBMC assays
| Drug | Mean synergy vol/antagonism vola | Antiviral effect |
|---|---|---|
| NNRTI | ||
| NVP | 73.1/−134.39 | Slightly synergistic |
| EFV | 4.01/0.00 | Additive |
| NRTI | ||
| AZT | 87.62/−45.52 | Slightly synergistic |
| 3TC | 17.32/−134.28 | Additive |
| d4T | 27.71/−68.38 | Additive |
| ddI | 297.47/−92.99 | Highly synergistic |
| PI | ||
| NFV | 116.85/−65.37 | Highly synergistic |
| IN | ||
| RAL | 54.12/−9.53 | Slightly synergistic |
a
Positive and negative values are represent synergistic and antagonistic interactions between F18 and other ARVs, respectively.